Table 2.

Treatment‐emergent adverse events related to study treatment

	Prexasertib 80 mg/m2 N = 6				Prexasertib 105 mg/m2 N = 6				Total N = 12
	Any grade	Grade 3	Grade 4	Grade 3 + 4	Any grade	Grade 3	Grade 4	Grade 3 + 4	Any grade	Grade 3	Grade 4	Grade 3 + 4
Any	6 (100)	2 (33.3)	4 (66.7)	6 (100)	6 (100)	3 (50.0)	3 (50.0)	6 (100)	12 (100)	5 (41.7)	7 (58.3)	12 (100)
Neutropenia	5 (83.3)	1 (16.7)	3 (50.0)	4 (66.7)	6 (100)	3 (50.0)	3 (50.0)	6 (100)	11 (91.7)	4 (33.3)	6 (50.0)	10 (83.3)
Leukopenia	6 (100)	1 (16.7)	3 (50.0)	4 (66.7)	6 (100)	4 (66.7)	1 (16.7)	5 (83.3)	12 (100)	5 (41.7)	4 (33.3)	9 (75.0)
Thrombocytopenia	4 (66.7)	2 (33.3)	1 (16.7)	3 (50.0)	4 (66.7)	1 (16.7)	0	1 (16.7)	8 (66.7)	3 (25.0)	1 (8.3)	4 (33.3)
Anemia	3 (50.0)	1 (16.7)	1 (16.7)	2 (33.3)	0	0	0	0	3 (25.0)	1 (8.3)	1 (8.3)	2 (16.7)
Febrile neutropenia	1 (16.7)	0	1 (16.7)	1 (16.7)	1 (16.7)	1 (16.7)	0	1 (16.7)	2 (16.7)	1 (8.3)	1 (8.3)	2 (16.7)
Lymphocytopenia	2 (33.3)	1 (16.7)	0	1 (16.7)	0	0	0	0	2 (16.7)	1 (8.3)	0	1 (8.3)
Atrial fibrillation	1 (16.7)	0	0	0	0	0	0	0	1 (8.3)	0	0	0
Constipation	2 (33.3)	0	0	0	1 (16.7)	0	0	0	3 (25.0)	0	0	0
ECG QT prolonged	2 (33.3)	0	0	0	0	0	0	0	2 (16.7)	0	0	0
Fatigue	1 (16.7)	0	0	0	1 (16.7)	0	0	0	2 (16.7)	0	0	0
Headache	0	0	0	0	1 (16.7)	0	0	0	1 (8.3)	0	0	0
Hypocalcemia	0	0	0	0	1 (16.7)	0	0	0	1 (8.3)	0	0	0
Lung infection	1 (16.7)	0	0	0	0	0	0	0	1 (8.3)	0	0	0
Nausea	2 (33.3)	0	0	0	0	0	0	0	2 (16.7)	0	0	0
Pyrexia	1 (16.7)	0	0	0	1 (16.7)	0	0	0	2 (16.7)	0	0	0
Rash maculopapular	1 (16.7)	0	0	0	1 (16.7)	0	0	0	2 (16.7)	0	0	0
Rash	1 (16.7)	0	0	0	0	0	0	0	1 (8.3)	0	0	0
Stomatitis	1 (16.7)	0	0	0	0	0	0	0	1 (8.3)	0	0	0
SVE	1 (16.7)	0	0	0	0	0	0	0	1 (8.3)	0	0	0

Treatment‐emergent adverse events related to study treatment by maximum National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) grade are listed by preferred term in decreasing frequency of grade 3 + 4 events.

Data are n (%).

ECG, electrocardiogram; SVE, supraventricular extrasystoles.